Abstract
Continuous renal replacement therapies (CRRT) are widely used for treatment of acute kidney injury in critically ill patients. Little attention has been paid to the potential adverse effects of CRRT related to extracorporeal circuit bioincompatibility. Limited available evidence suggests that intermittent dialysis may compromise hepatosplanchnic perfusion in acute renal failure patients. By contrast, there are no data on the bio(in)compatibility indices in patients treated by CRRT. To investigate this issue, we utilized a long-term porcine model allowing a broad insight into organ hemodynamic, microvascular, metabolic and other pathways not accessible in human medicine.
Highlights
There is considerable uncertainty about the reproducibility of the various instruments used to measure dyspnea, their ability to reflect changes in symptoms, whether they accurately reflect the patient’s experience and if its evolution is similar between acute heart failure syndrome patients and nonacute heart failure syndrome patients
There were no significant differences between the two groups with respect to organ-failure free days (22 vs. 25.5 days, P = 0.11), ventilator-free days (16.5 vs. 23 days, P = 0.15), length of pediatric critical care unit stay (8 vs. 8.5 days, P = 0.93), or the adverse and serious adverse event rate ratios (12.0%, 95% cardiac index (CI) = –2.6 to 26.7, P = 0.15; and 3.2%, 95% CI = –13.7 to 7.8, P = 0.55, respectively)
Results of this study show that early tracheostomy, if perioperative complications
Summary
There is considerable uncertainty about the reproducibility of the various instruments used to measure dyspnea, their ability to reflect changes in symptoms, whether they accurately reflect the patient’s experience and if its evolution is similar between acute heart failure syndrome patients and nonacute heart failure syndrome patients. Conclusions Our data demonstrate that critically ill patients may be exposed to a higher FiO2 than that required to maintain adequate oxygenation These results highlight an area of ICU care that has received little study, with no published clinical trials examining the effect of FiO2 on outcome. Results Age, sex, the underlying disease and tumour stage (TNM classification), type of previous anticancer treatment, performance status, severity scores (APACHE II, Simplified Acute Physiology Score II, Sequential Organ Failure Assessment), ICU and hospital mortalities and hospital outcome at 3, 6 and 12 months were analysed. Clinical data of 277 post-transplantation patients admitted to the ICU were collected at admission and the SAPS 3 and APACHE II score calculated with respective estimated mortality rates.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call